ASCO: Germline Variation Does Not Predict TaxaneTaxane-Induced Peripheral Neuropathy
07 Jun 2024
Clinical ResultASCO
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel (every three weeks) for early-stage breast cancer, according to a study published online June 3 in the Journal of Clinical Oncology to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
Bryan P. Schneider, M.D., from the Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, and colleagues validated germline predictors of TIPN and compared rates of TIPN and dose reductions in Black women receiving (neo)adjuvant paclitaxel once weekly and docetaxel once every three weeks for early-stage breast cancer. Germline neuropathy risk was determined by performing genotyping; genotype data were available for 240 patients. Of the patients, 91 of 117 receiving once-weekly paclitaxel and 87 of 118 receiving once-every-three-weeks docetaxel were classified as high-risk.
The researchers observed no significant difference in physician-reported grade 2 to 4 TIPN in high- versus low-risk genotype groups with once-weekly paclitaxel or once-every-three-weeks docetaxel. The once-weekly paclitaxel group had significantly higher grade 2 to 4 TIPN than the once-every-three-weeks docetaxel arm by physician-rated Common Terminology Criteria for Adverse Events (CTCAE) (45 versus 29 percent) and patient-reported outcome CTCAE (40 versus 24 percent). More dose reductions because of TIPN or any cause occurred in patients receiving once-weekly paclitaxel.
"Key, clinically relevant long-term follow-up data will be crucial to understand the true scope of impact," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text
More Information
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.